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a  b  s  t  r  a  c  t
Ivy  leaves  dry  extract  is registered  as an  expectorant  in  patients  with  respiratory  diseases  associated
with  productive  cough.  Next  to  its secretolytical  properties,  bronchospasmolytical  effects  are  described.
However  only  limited  data  exist  about  a possible  therapeutical  effect  in asthmatic  patients.
In  this  double  blind,  placebo-controlled,  randomized  cross-over  study,  30  children  (median  age  9.07
years  (min–max:  6–11))  suffering  from  partial  or uncontrolled  mild persistent  allergic  asthma  despite
long-term  treatment  with 400  g budesonide  equivalent  were  investigated.  After  a four  week  run-in
period,  patients  either  received  ivy  leaves  dry extract  for four  weeks  in  addition  to  their  inhaled  cortico-
steroid  therapy  or placebo,  followed  by  a wash-out  phase  before  switching  to  the  other  treatment  arm.
Lung  function,  FeNO,  exhaled  breath  condensate  pH  and  life  quality  was  analyzed  after  each  treatment
period.
There was  a  signiﬁcant  improvement  of MEF75-25, MEF25 and  VC  after treatment  with  ivy leaves  dry
extract  (MEF75-25 change  in  the  mean  0.115  l/s,  p = 0.044;  MEF25 change  in  the mean  0.086  l/s,  p =  0.041;
VC change  in the  mean  0.052  l, p  = 0.044),  but  not  after treatment  with  placebo.  For  the  primary  outcome
parameters  (relative  change  of  FEV1 and  MEF75-25 before  bronchodilation)  no treatment  effect  could  be
detected  in the  cross-over  analysis  (FEV1 p  = 0.6763  and MEF75-25 p = 0.6953).
This  proof-of-concept  study  indicates  that  children  with  mild  uncontrolled  asthma  despite  regular
inhaled  corticosteroid  therapy  might  beneﬁt  from  an  additional  therapy  with  ivy  leaves  dry  extract.
However,  further  studies  are  needed.
© 2014  The  Authors.  Published  by  Elsevier  GmbH.  This  is  an  open  access  article  under  the  CCntroduction
Since decades, ivy leaves dry extract is applied for the treat-
ent of respiratory diseases accompanied by productive cough.
he tolerance and safety of different ivy leaves extract-containing
reparations has been tested and conﬁrmed in several studies
Fazio et al. 2009; Kraft 2004).
The effect of ivy leaves dry extract is based on its secretolyt-
cal and broncholytical properties. The main active compounds
re saponins (Cioacá et al. 1978; Trute et al. 1997; Bedir et al.
000), especially alpha-hederin represents the most important
aponin molecule responsible for the therapeutic effect (Sieben
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et al. 2009). Alpha-hederin inhibits the internalization of the 2-
receptor leading to an increased adrenergic accessibility of the cells.
Subsequently, type II alveolar epithelial cells generate more surfac-
tant yielding to the secretolytic activity by reduction of the mucus
viscosity. Similarly, the bronchodilating effect can be related to the
increased 2-adrenergic activity resulting in a higher sensitivity to
spasmolytics such as adrenalin, the strongest physiological bron-
chodilator (Hegener et al. 2004). In a double blind comparative
study against Ambroxol, the ivy leaves dry extract demonstrated
non-inferiority concerning relevant clinical and lung function out-
come parameters (Meyer-Wegener et al. 1993).
Bronchial asthma is a chronic inﬂammatory disease with recur-
rent obstruction due to bronchospasm and increased mucus
secretion. Preliminary clinical studies with asthmatic children
treated with an inhaled corticosteroid indicated an improvement of
various lung function parameters after three days of add-on therapy
with ivy leaves dry extract (Gulyas et al. 1997; Mansfeld et al. 1997;
Mansfeld et al. 1998). However, small patient number, the short
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Table  1
Primary and secondary endpoints of the study.
Primary endpoints MEF75-25 before bronchodilation – relative change
FEV1 before bronchodilation – relative change
Secondary endpoints MEF75-25 before bronchodilation – absolute change
FEV1 before bronchodilation – absolute change
FeNO
Exhaled breath condensate pH
Peak ﬂow proﬁle
Lungfunction parameters before and after
bronchodilation (RAW, TLC, VC, MEF75-25, FEV1,
FVC, RV, FRC, MEF50, MEF25)
Emergency treatment (beta agonist demand)
Number of days with asthma symptoms
PAQLQ result
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Fig. 1. Study visits took place every 28–30 days. Splitted into two  treatment arms,
every patient received verum (Prospan® Cough Syrup) and placebo. The treatmentACQ result
Tolerance
uration, the lacking of a placebo control group and the exclusive
eport of changes of subjective parameters are examples for limi-
ations in further studies (Huntley and Ernst 2000; Hofmann et al.
003; Clark et al. 2010).
The aim of our study was therefore to investigate the effect of
n add-on therapy with ivy leaves dry extract in children with mild
ersistent asthma treated by an inhaled corticosteroid.
aterials and methods
This double-blind, placebo controlled, randomized cross-over
tudy was conducted in compliance with the ICH-GCP guideline.
t was approved by the local Ethics Committee and received con-
ent from Bundesinstitut für Arzneimittel und Medizinprodukte
BfArM) and followed the guidelines of the Declaration of Helsinki
nd Tokyo for humans. A parent or guardian of every child and if
ossible the child in person provided written informed consent. Pri-
ary and secondary endpoints were deﬁned according to Table 1.
tudy subjects
30 asthmatic children aged 6–12 years of both genders suffer-
ng from partial or uncontrolled mild persistent allergic bronchial
sthma with a grade II severity in terms of the NVL Asthma Ver-
ion 1.3.2011 (Bundesärztekammer 2009) for at least one year
ere enclosed in the study. Lack of asthma control was deﬁned as
mprovement of the FEV1 ≥ 12% after 2 puffs of 100 g terbutaline
uring steroid monotherapy with 400 g budesonide equiva-
ent/day or an ACT score ≤ 19 (asthma control test). All subjects
ere included from May  2012 until January 2013. Patients were
xcluded if they had an acute respiratory infection within the pre-
ious four weeks, a history of bronchopulmonary dysplasia, vocal
ord dysfunction, gastro-oesophageal reﬂux, hereditary fructose
ntolerance or known chronic diseases.
ourse of the study and procedures
After initial screening, subjects had to be adjusted to 400 g
udesonide equivalent/day as monotherapy if necessary at the
eginning of the run-in phase. The inhaled corticosteroid dosage
emained unchanged throughout the whole study. If a patholog-
cal lung function (improvement of FEV1 after bronchodilation of
t least 12%) or ACT (less than 20 points) was ascertained at study
isit 2, the patient was deﬁnitively registered in the trial.
Study treatment was given as Prospan® Cough Syrup (ivy leaves
ry extract (5–7, 5:1), extractive agent ethanol 30% (m/m)) in a
aily dosage of 2× 5 ml,  corresponding to 70 mg  extract. The extract
s well characterized (Landgrebe et al. 1999). An inactive, iden-
ical ﬂavored, look-alike syrup was used in the same quantity asand the placebo period were separated by a wash-out phase of 28–30 days. The end
of  the trial was  after a four weeks run-out phase.
placebo. The administration of the trial medication was performed
randomized, double-blind, cross-over designed according to Fig. 1
for 28–30 days respectively.
Blinded study medication and placebo were obtained from
Engelhard Arzneimittel GmbH & Co. KG. The placebo was manufac-
tured according to GMP  standards (good manufacturing practice).
The investigational products were packed in an individual way  for
each patient, who entered the study. All bottles of investigational
drug were returned and weighted to supervise the compliance
additional to the entry made in the diary. An intake of study medi-
cation equal or more than 80% of the total amount was considered
acceptable.
In total ﬁve to six study appointments took place every 28–30
days. At each visit a bodyplethysmography was conducted, the
FeNO and exhaled breath condensate pH (EBC-pH) were mea-
sured. Additionally two questionnaires concerning life quality
(Standardized Paediatric Asthma Quality of Life Questionnaire
(PAQLQ(S)), Asthma Control Questionnaire (ACQ)) were ﬁlled in
by the participants in absence of the parents. Peak-ﬂow mea-
surements were performed twice daily at home and documented
in a diary together with information concerning the intake of
the investigational and the permanent medication. Furthermore,
asthma symptoms (cough, breathing difﬁculties) and concomitant
treatment had to be documented. Concomitant medication being
considered to inﬂuence bronchial asthma was not permitted in
the trial (leukotriene antagonists, anticholinergics, long acting beta
agonists, beta blockers, methylxanthines, anti-IgE treatment, cro-
moglycin sodium/nedocromil sodium).
The lung function parameters were measured with a body-
plethysmograph (MasterLab, Jaeger, Höchberg, Germany). Param-
eters were expressed as a percentage of predicted value. FeNO
was measured with a chemiluminescence analyzer (CLD 88 sp;
Eco Medics, Duernten, Switzerland), expressed in parts per billion
(Baraldi and de Jongste 2001). Exhaled breath condensate (EBC) was
collected using a modiﬁed, commercially available breath conden-
sate sampler (EcoScreen; Jaeger, Höchberg, Germany) and EBC-pH
was analyzed as described elsewhere (Vogelberg et al. 2007). All
measurements were conducted according to the American Thoracic
Society/European Respiratory Society criteria (Beydon et al. 2007).
Statistical analyses
Complete blinding of patients, investigators and statisticians
was maintained until all data had been locked. Thereafter data
were grouped according to treatment code without revealing their
identity. The data were unblinded after completion of the statis-
tical analyses. Data were analyzed based on the intention-to-treat
principle. The SPSS 21 and SAS 9.2 software package were used.The conﬁrmatory data analysis (done for the primary endpoint)
was done with aid of the generalized linear model. The sec-
ondary outcomes were evaluated and analyzed according to their
scale level: For continuous endpoints mean values and conﬁdence
1218 S. Zeil et al. / Phytomedicine 
Table  2
Demographic characteristics of the subjects.
Characteristics Group Total
Placebo-Prospan® Prospan®-placebo
No. 15 15 30
Male/female 7/8 10/5 17/13
Median age in
years
(min./max.)
9.07 (6/11) 9.07 (6/11) 9.07 (6/11)
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children with all grades of asthma severity show an inﬂammation
T
Cntervals or medians and quartiles were used, for categorical end-
oints absolute and relative frequencies were applied. Depending
n the distribution of the variables the t-test, the U-test and the
2-test were used. For intra-individual comparison the paired t-test
as used in case of normally distributed variables and the Wilcoxon
est in case of non-normally distributed variables. All statistical
ests were performed at the signiﬁcance level  ˛ = 0.05. Adverse
vents were evaluated in consideration of frequency, intensity and
ausality to study drug.
esults
Thirty children were randomized (Table 2). One child with-
rew prematurely from the study during the ﬁrst treatment period
ecause the parents stopped the long-term treatment with inhaled
teroids. All other children regularly terminated the study and
eturned diary cards covering the whole study period. Five sub-
ects showed treatment compliance below 80%. Three of them took
he study medication twice daily with too low medication volume.
For the primary outcome parameters (relative change of FEV1
nd MEF75-25 before bronchodilation) no signiﬁcant treatment
ffect could be detected in the cross-over analysis (FEV1 p = 0.6763
nd MEF75-25 p = 0.6953). However there was a signiﬁcant period
ffect concerning FEV1 (p = 0.0031).
Concerning the secondary endpoints signiﬁcant effects during
reatment with ivy leaves dry extract resulted for the abso-
ute change of MEF75-25, MEF25 and VC before bronchodilation
MEF75-25 change in the mean 0.115 l/s, p = 0.044; MEF25 change
n the mean 0.086 l/s, p = 0.041; VC change in the mean 0.052 l, = 0.044). Within the placebo group no treatment effect was
etected. The respective differences (between parameters before
reatment with ivy leaves dry extract/placebo and parameters after
able 3
hange in the means, standard deviation and signiﬁcance after treatment with placebo a
Paired differences
Before placebo – after placebo 
Change in the mean Standard deviation Signiﬁcanc
FEV1 −0.052 0.117 0.021 
MEF75-25 −0.099 0.311 0.093 
MEF25 −0.075 0.231 0.087 
VC  0.001 0.138 0.958 
RAW 0.020 0.158 0.493 
TLC  −0.057 0.251 0.211 
FVC  −0.018 0.141 0.499 
RV  −0.065 0.305 0.255 
FRC  .0.040 0.229 0.342 
MEF50 −0.107 0.316 0.075 
FeNO 5.430 14.891 0.069 
EBC-pH −0.080 1.009 0.671 
Peak  ﬂow −15.333 43.225 0.062 
ACQ  0.933 1.893 0.011 
PAQLQ −2.533 6.877 0.053 21 (2014) 1216–1220
treatment with ivy leaves dried extract/placebo) did not differ sig-
niﬁcantly.
For the absolute change of FEV1 a period effect was  detected
analogous to the relative change (ivy leaves dry extract median
change 0.059 l, p = 0.16; placebo median change 0.052 l, p = 0.021).
The differences did not differ signiﬁcantly (p = 0.835).
The ACQ score decreased signiﬁcantly with placebo (change in
the mean 0.93 points, p = 0.011), but not with ivy leaves dry extract.
For the parameter RAW, TLC, FVC, RV, FRC, MEF50 before and
after bronchodilation, FEV1, VC, MEF75-25 after bronchodilation as
well as for FeNO, EBC-pH, peak ﬂow und PAQLQ-Score no signiﬁ-
cant changes after treatment with ivy leaves dry extract nor with
placebo were found (Table 3).
Discussion
The aim of this study was to evaluate a possible beneﬁt of an add
on therapy with ivy leaves dry extract in children with partial or
uncontrolled mild persistent asthma, treated with inhaled corticos-
teroids. After four weeks of treatment with ivy leaves dry extract,
a partial improvement of lung function compared to placebo was
demonstrated. Concerning the primary endpoint of the study, the
FEV1, no signiﬁcant change was  observed. For the parameters
MEF75-25, MEF25 and VC which are among the secondary endpoints
of the study, a signiﬁcant difference between active treatment and
placebo was  shown.
Although FEV1 represents a relatively objective and repro-
ducible parameter and is listed in the current guidelines for asthma
as a major factor in assessing asthma severity, it is an ongoing
discussion whether FEV1 is a good parameter for asthma sever-
ity in childhood. Several studies demonstrated that children with
bronchial asthma, unlike adults, often meet the clinical criteria for
severe asthma despite having a normal or only slightly decreased
FEV1 (Paull et al. 2005; The Childhood Asthma Management
Program Research Group 2000; Bacharier et al. 2004; Galant et al.
2007). One reason, that FEV1 remains normal in children, even if
already a severe airway obstruction is present, may  be due to the
altered anatomy of the respiratory tract compared to adults (a rel-
atively large airway diameter in comparison to the lung volume).
Additionally there seems to be different disease localizations, forof the peripheral airways with only little impairment of the large
airways (Tashkin 2002). The associated peripheral airway obstruc-
tion remains unreﬂected by FEV1. These ﬁndings might provide the
nd ivy leaves dry extract before bronchodilation for 28–30 days.
Before Prospan® – after Prospan®
e Change in the mean Standard deviation Signiﬁcance
−0.125 0.107 0.016
−0.115 0.294 0.044
−0.086 0.215 0.041
−0.052 0.133 0.044
0.077 0.246 0.105
−0.046 0.308 0.433
−0.045 0.140 0.096
0.013 0.299 0.827
0.039 0.241 0.388
−0.111 0.309 0.063
3.510 15.456 0.232
0.161 0.786 0.287
−7.890 24.140 0.089
0.655 3.588 0.334
−2.655 9.994 0.164
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vidence, that for children, MEF75-25 might be regarded as the most
igniﬁcant parameter for airway obstruction (Lebecque et al. 1993;
lberts et al. 1994; Simon et al. 2010) and should be established as
cceptable endpoint in clinical trials concerning asthmatic children
Rao et al. 2012).
In our study, relevant alterations in lung function occurred
ainly in parameters reﬂecting peripheral airways. This periph-
rally enhanced effect of the study medication, inhibiting the
nternalization of the 2-receptor, might be explained by the dis-
ribution of this receptor in the lung. In various studies using
ifferent investigational techniques it could be demonstrated that
he 2-receptor density increase with increasing airway genera-
ion (Johnson 1998; Ueki et al. 1993). Due to the otherwise stable
ong-term medication during the study, the improvement of lung
unction might therefore be attributed to the add-on treatment
ith ivy leaves dry extract.
To avoid a possible overlap between the two  treatment peri-
ds, a prolonged wash-out period was deﬁned within the study
rotocol. In addition subjects had to take a standardized baseline
herapy to improve comparability between the study groups. Ther-
py adherence and a correct grading of the asthma severity were
uaranteed by the run-in period.
In contrast to changes of the lung function, quality of life was
ot signiﬁcantly inﬂuenced by the intervention as measured by the
AQLQ(S). However, due to the short duration of the study and the
evel of lung function changes, this result is not really surprising. In
ddition, asthmatic children are known to have a bad perception of
heir asthma severity (Horak et al. 2003).
Within both study arms, a marked period effect in lung function
mprovement could be demonstrated, especially during the ﬁrst
reatment episode. This effect can be attributed to the signiﬁcantly
etter therapy adherence of the patients during the study. Over the
ntire study period and in all participants a very high adherence
as recorded. Next to the high frequency of study visits with the
pportunity to control and encourage therapy adherence, an opti-
al  doctor-patient relationship further may  account for this effect
Benedetti 2013; Di Blasi et al. 2001). In addition the regular docu-
entation of the treatment within the diary might have improved
he therapy adherence. Moreover, the fact that the add-on therapy
as performed with a herbal medication, lead to a high acceptance
specially from parental side.
In summary, this proof-of-concept study demonstrates a signif-
cant improvement in lung function parameters in children with
ild persistent, uncontrolled asthma despite regular therapy with
n inhaled corticosteroid by an additional treatment with ivy leaves
ry extract. Further studies are needed to evaluate whether the
upplementary treatment with ivy leaves dry extract might be a
reatment option in asthmatic patients.
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